Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts. more
Time Frame | COLL | Sector | S&P500 |
---|---|---|---|
1-Week Return | -1.3% | -2.12% | -3% |
1-Month Return | -1% | -3.42% | -0.73% |
3-Month Return | -23.98% | -11.13% | 2.87% |
6-Month Return | -5.95% | -5.74% | 7.17% |
1-Year Return | -0.44% | 3.97% | 25.31% |
3-Year Return | 57.48% | 1.05% | 28.38% |
5-Year Return | 50.91% | 34.37% | 81.89% |
10-Year Return | 141.66% | 97.88% | 183.27% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 296.70M | 310.02M | 276.87M | 463.93M | 566.77M | [{"date":"2019-12-31","value":52.35,"profit":true},{"date":"2020-12-31","value":54.7,"profit":true},{"date":"2021-12-31","value":48.85,"profit":true},{"date":"2022-12-31","value":81.86,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Cost of Revenue | 193.66M | 130.18M | 126.25M | 254.44M | 240.60M | [{"date":"2019-12-31","value":76.11,"profit":true},{"date":"2020-12-31","value":51.16,"profit":true},{"date":"2021-12-31","value":49.62,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":94.56,"profit":true}] |
Gross Profit | 103.04M | 179.84M | 150.62M | 209.49M | 326.17M | [{"date":"2019-12-31","value":31.59,"profit":true},{"date":"2020-12-31","value":55.14,"profit":true},{"date":"2021-12-31","value":46.18,"profit":true},{"date":"2022-12-31","value":64.23,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Margin | 34.73% | 58.01% | 54.40% | 45.15% | 57.55% | [{"date":"2019-12-31","value":59.87,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":93.78,"profit":true},{"date":"2022-12-31","value":77.84,"profit":true},{"date":"2023-12-31","value":99.21,"profit":true}] |
Operating Expenses | 126.79M | 123.60M | 128.41M | 176.17M | 159.21M | [{"date":"2019-12-31","value":71.97,"profit":true},{"date":"2020-12-31","value":70.16,"profit":true},{"date":"2021-12-31","value":72.89,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":90.37,"profit":true}] |
Operating Income | (23.75M) | (5.09M) | (46.70M) | (104.57M) | 166.96M | [{"date":"2019-12-31","value":-14.22,"profit":false},{"date":"2020-12-31","value":-3.05,"profit":false},{"date":"2021-12-31","value":-27.97,"profit":false},{"date":"2022-12-31","value":-62.63,"profit":false},{"date":"2023-12-31","value":100,"profit":true}] |
Total Non-Operating Income/Expense | 2.05M | (57.30M) | (42.00M) | (124.33M) | (158.95M) | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":-2792.4,"profit":false},{"date":"2021-12-31","value":-2046.98,"profit":false},{"date":"2022-12-31","value":-6059.06,"profit":false},{"date":"2023-12-31","value":-7746.2,"profit":false}] |
Pre-Tax Income | (22.72M) | 27.58M | (3.37M) | (28.85M) | 75.73M | [{"date":"2019-12-31","value":-30,"profit":false},{"date":"2020-12-31","value":36.42,"profit":true},{"date":"2021-12-31","value":-4.46,"profit":false},{"date":"2022-12-31","value":-38.09,"profit":false},{"date":"2023-12-31","value":100,"profit":true}] |
Income Taxes | (14.57M) | 830.00K | (74.89M) | (3.85M) | 27.58M | [{"date":"2019-12-31","value":-52.85,"profit":false},{"date":"2020-12-31","value":3.01,"profit":true},{"date":"2021-12-31","value":-271.56,"profit":false},{"date":"2022-12-31","value":-13.94,"profit":false},{"date":"2023-12-31","value":100,"profit":true}] |
Income After Taxes | (8.15M) | 26.75M | 71.52M | (25.00M) | 48.16M | [{"date":"2019-12-31","value":-11.39,"profit":false},{"date":"2020-12-31","value":37.41,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-34.96,"profit":false},{"date":"2023-12-31","value":67.33,"profit":true}] |
Income From Continuous Operations | (22.72M) | 26.75M | 71.52M | (25.00M) | 48.16M | [{"date":"2019-12-31","value":-31.77,"profit":false},{"date":"2020-12-31","value":37.41,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-34.96,"profit":false},{"date":"2023-12-31","value":67.33,"profit":true}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (8.15M) | 26.75M | 71.52M | (25.00M) | 48.16M | [{"date":"2019-12-31","value":-11.39,"profit":false},{"date":"2020-12-31","value":37.41,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-34.96,"profit":false},{"date":"2023-12-31","value":67.33,"profit":true}] |
EPS (Diluted) | (0.68) | 0.76 | 0.39 | 0.56 | 1.18 | [{"date":"2019-12-31","value":-57.63,"profit":false},{"date":"2020-12-31","value":64.41,"profit":true},{"date":"2021-12-31","value":33.05,"profit":true},{"date":"2022-12-31","value":47.46,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
These ratios help you determine the liquidity of the company. Higher is better.
COLL | |
---|---|
Cash Ratio | 0.26 |
Current Ratio | 0.97 |
Quick Ratio | 0.88 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
COLL | |
---|---|
ROA (LTM) | 9.68% |
ROE (LTM) | 42.89% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
COLL | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.86 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.14 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
COLL | |
---|---|
Trailing PE | 13.01 |
Forward PE | 4.80 |
P/S (TTM) | 1.64 |
P/B | 4.19 |
Price/FCF | NM |
EV/R | 2.90 |
EV/Ebitda | 5.01 |
PEG | NM |
Collegium Pharmaceutical Inc (COLL) share price today is $29.7
Yes, Indians can buy shares of Collegium Pharmaceutical Inc (COLL) on Vested. To buy Collegium Pharmaceutical Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in COLL stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Collegium Pharmaceutical Inc (COLL) via the Vested app. You can start investing in Collegium Pharmaceutical Inc (COLL) with a minimum investment of $1.
You can invest in shares of Collegium Pharmaceutical Inc (COLL) via Vested in three simple steps:
The 52-week high price of Collegium Pharmaceutical Inc (COLL) is $42.29. The 52-week low price of Collegium Pharmaceutical Inc (COLL) is $28.97.
The price-to-earnings (P/E) ratio of Collegium Pharmaceutical Inc (COLL) is 12.8291
The price-to-book (P/B) ratio of Collegium Pharmaceutical Inc (COLL) is 4.19
The dividend yield of Collegium Pharmaceutical Inc (COLL) is 0.00%
The market capitalization of Collegium Pharmaceutical Inc (COLL) is $968.15M
The stock symbol (or ticker) of Collegium Pharmaceutical Inc is COLL